CU20170089A7 - Derivados de quinazolina utilizados para tratar el vih - Google Patents
Derivados de quinazolina utilizados para tratar el vihInfo
- Publication number
- CU20170089A7 CU20170089A7 CUP2017000089A CU20170089A CU20170089A7 CU 20170089 A7 CU20170089 A7 CU 20170089A7 CU P2017000089 A CUP2017000089 A CU P2017000089A CU 20170089 A CU20170089 A CU 20170089A CU 20170089 A7 CU20170089 A7 CU 20170089A7
- Authority
- CU
- Cuba
- Prior art keywords
- derivatives used
- quinazoline derivatives
- treat hiv
- compounds
- formula
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Se describen en el presente documento compuestos de Formula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>y tautómeros y sales farmacéuticas de los mismos, métodos para prepararlos, composiciones y formulaciones que contienen dichos compuestos, los cuales son útiles en el tratamiento y prevención de infección por VIH en un sujeto.<br /> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096748P | 2014-12-24 | 2014-12-24 | |
| PCT/US2015/000460 WO2016105564A1 (en) | 2014-12-24 | 2015-12-23 | Quinazoline derivatives used to treat hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20170089A7 true CU20170089A7 (es) | 2017-11-07 |
Family
ID=55305044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2017000089A CU20170089A7 (es) | 2014-12-24 | 2015-12-23 | Derivados de quinazolina utilizados para tratar el vih |
Country Status (41)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| BR112017013491A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de pirimidina fundida para o tratamento de hiv |
| NZ733125A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
| LT3236972T (lt) | 2014-12-26 | 2021-11-10 | Emory University | Antivirusiniai n4-hidroksicitidino dariniai |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| BR112018071678B1 (pt) | 2016-08-19 | 2021-01-26 | Gilead Sciences, Inc. | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| LT3706762T (lt) | 2017-12-07 | 2024-12-27 | Emory University | N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai |
| KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
| CA3281991A1 (en) | 2018-02-16 | 2025-11-29 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
| WO2019204768A1 (en) * | 2018-04-20 | 2019-10-24 | The Regents Of The University Of California | Beta-adrenergic receptor allosteric modulators |
| JP2021530523A (ja) | 2018-07-16 | 2021-11-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のためのカプシド阻害剤 |
| EP3902805A4 (en) | 2018-12-28 | 2023-03-01 | SPV Therapeutics Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
| SI3938047T1 (sl) | 2019-03-22 | 2022-10-28 | Gilead Sciences, Inc. | Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba |
| WO2020214647A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| EP4643882A2 (en) | 2019-11-26 | 2025-11-05 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| TWI845826B (zh) | 2020-03-20 | 2024-06-21 | 美商基利科學股份有限公司 | 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法 |
| JP6996032B1 (ja) | 2020-04-24 | 2022-01-17 | 大日本住友製薬株式会社 | ２－ヘテロアリールアミノキナゾリノン誘導体 |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| US20220144923A1 (en) | 2020-11-11 | 2022-05-12 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| CN118355020A (zh) | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| FI4445900T3 (fi) | 2021-12-03 | 2025-08-05 | Gilead Sciences Inc | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| EP4547659A1 (en) | 2022-07-01 | 2025-05-07 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| CA3265134A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AU2024259111A1 (en) | 2023-04-19 | 2025-10-16 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025260028A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ197420A (en) | 1980-07-01 | 1984-04-27 | Ici Australia Ltd | -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives |
| JPH11209350A (ja) | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| WO2001021598A1 (en) | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| AU1462101A (en) | 1999-11-22 | 2001-06-04 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
| WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
| CN1474815A (zh) | 2000-09-20 | 2004-02-11 | Ĭ��ר���ɷ�����˾ | 4-氨基-喹唑啉 |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| WO2004108711A1 (en) | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrazinil quinazoline derivatives for use in the treatment of tumours |
| JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| JP2008508291A (ja) | 2004-07-27 | 2008-03-21 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体 |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| KR20070085286A (ko) | 2004-10-29 | 2007-08-27 | 티보텍 파마슈티칼즈 리미티드 | Ｈｉｖ를 저해하는 바이사이클릭 피리미딘 유도체 |
| WO2006071095A1 (en) | 2004-12-31 | 2006-07-06 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
| WO2006099301A2 (en) | 2005-03-10 | 2006-09-21 | The Regents Of The University Of California | Apoptosis inhibitors |
| JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| WO2007000240A1 (en) | 2005-06-28 | 2007-01-04 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
| UA93882C2 (ru) | 2005-07-26 | 2011-03-25 | Санофи-Авентис | Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| RU2457204C2 (ru) | 2006-01-27 | 2012-07-27 | Файброджен, Инк. | Цианоизохинолиновые соединения (варианты), фармацевтическая композиция на их основе, способ ингибирования активности гидроксилазы гипоксия-индуцибельного фактора (hif) и способ лечения и/или профилактики состояния, связанного с hif, и/или состояния, связанного с эритропоэтином, и/или анемии |
| AR060358A1 (es) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2008011109A2 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted pyridone compounds and methods of use |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| WO2008050808A1 (fr) | 2006-10-24 | 2008-05-02 | Kyowa Hakko Kirin Co., Ltd. | Dérivé de 2-aminoquinazoline |
| DE602007013950D1 (de) | 2006-12-27 | 2011-05-26 | Sanofi Aventis | Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate |
| MY150746A (en) | 2006-12-27 | 2014-02-28 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| NZ577980A (en) | 2006-12-27 | 2012-01-12 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
| US20090004185A1 (en) | 2007-01-11 | 2009-01-01 | Wyeth | Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents |
| WO2008122614A1 (en) | 2007-04-06 | 2008-10-16 | Novartis Ag | 2, 6-naphthyridine derivatives as protein kinase modulators |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| JPWO2009131173A1 (ja) | 2008-04-23 | 2011-08-18 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| CA2725014C (en) | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US8573519B2 (en) | 2008-08-15 | 2013-11-05 | Basf Se | Process for producing nanoscale organic solid particles |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| PE20120424A1 (es) | 2008-12-29 | 2012-05-04 | Fovea Pharmaceuticals | Compuestos de quinazolina sustituidos |
| EP2416660B1 (en) | 2009-04-07 | 2014-07-02 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| WO2011035416A1 (en) | 2009-09-25 | 2011-03-31 | Aegera Therapeutics Inc. | Hsp90 modulating compounds, compositions, methods and uses |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| TW201210597A (en) | 2010-06-09 | 2012-03-16 | Gilead Sciences Inc | Inhibitors of hepatitis C virus |
| AR081960A1 (es) | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| CA2803890A1 (en) | 2010-06-25 | 2011-12-29 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
| SG186820A1 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht- 2 -ylacetic acid derivatives to treat aids |
| BR112012033689A2 (pt) | 2010-07-02 | 2019-09-24 | Gilead Sciences Inc | derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais |
| KR20130141500A (ko) | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| KR20120038060A (ko) | 2010-10-13 | 2012-04-23 | 롬엔드하스전자재료코리아유한회사 | 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| CA2817460A1 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| ES2615734T3 (es) | 2011-04-21 | 2017-06-08 | Gilead Sciences, Inc. | Compuestos de benzotiazol y su uso farmacéutico |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
| MX2014005002A (es) | 2012-04-20 | 2014-07-09 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih. |
| MX344879B (es) | 2012-12-21 | 2017-01-11 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| RU2015131006A (ru) | 2012-12-27 | 2017-01-30 | Джапан Тобакко Инк. | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| EP2769723A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| US9914709B2 (en) | 2013-06-21 | 2018-03-13 | Yale University | Compositions and methods of treating HIV-1 infections using same |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| BR112017013491A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de pirimidina fundida para o tratamento de hiv |
| NZ733125A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
-
2015
- 2015-12-18 TW TW104142712A patent/TWI699355B/zh active
- 2015-12-18 TW TW109122699A patent/TWI770552B/zh active
- 2015-12-18 TW TW111121406A patent/TW202237569A/zh unknown
- 2015-12-22 AR ARP150104262A patent/AR103252A1/es unknown
- 2015-12-23 PT PT15832711T patent/PT3237398T/pt unknown
- 2015-12-23 HU HUE18213309A patent/HUE058296T2/hu unknown
- 2015-12-23 PL PL21187414.4T patent/PL3960735T3/pl unknown
- 2015-12-23 UA UAA201707115A patent/UA117796C2/uk unknown
- 2015-12-23 PE PE2017001139A patent/PE20171306A1/es unknown
- 2015-12-23 SI SI201531719T patent/SI3521282T1/sl unknown
- 2015-12-23 BR BR102015032361-1A patent/BR102015032361B1/pt active IP Right Grant
- 2015-12-23 AU AU2015371198A patent/AU2015371198B2/en active Active
- 2015-12-23 ES ES21187414T patent/ES2964395T3/es active Active
- 2015-12-23 EA EA201791256A patent/EA035746B1/ru unknown
- 2015-12-23 KR KR1020197034431A patent/KR102288855B1/ko active Active
- 2015-12-23 SG SG10202101143VA patent/SG10202101143VA/en unknown
- 2015-12-23 PL PL18213309T patent/PL3521282T3/pl unknown
- 2015-12-23 MY MYPI2017702362A patent/MY189761A/en unknown
- 2015-12-23 KR KR1020177020449A patent/KR102049476B1/ko active Active
- 2015-12-23 JP JP2017534259A patent/JP6367489B2/ja active Active
- 2015-12-23 HK HK18103444.6A patent/HK1244001B/en unknown
- 2015-12-23 SI SI201530560T patent/SI3237398T1/sl unknown
- 2015-12-23 CA CA2972021A patent/CA2972021C/en active Active
- 2015-12-23 US US14/998,042 patent/US9730936B2/en active Active
- 2015-12-23 LT LTEP18213309.0T patent/LT3521282T/lt unknown
- 2015-12-23 WO PCT/US2015/000460 patent/WO2016105564A1/en not_active Ceased
- 2015-12-23 CN CN201580076616.XA patent/CN107278201B/zh active Active
- 2015-12-23 SG SG11201705215PA patent/SG11201705215PA/en unknown
- 2015-12-23 HR HRP20211543TT patent/HRP20211543T1/hr unknown
- 2015-12-23 DK DK18213309.0T patent/DK3521282T3/da active
- 2015-12-23 EP EP23196262.2A patent/EP4302830A3/en active Pending
- 2015-12-23 ES ES15832711T patent/ES2715507T3/es active Active
- 2015-12-23 EP EP15832711.4A patent/EP3237398B1/en active Active
- 2015-12-23 NZ NZ733174A patent/NZ733174A/en unknown
- 2015-12-23 EA EA202091115A patent/EA202091115A1/ru unknown
- 2015-12-23 MX MX2017008521A patent/MX367574B/es active IP Right Grant
- 2015-12-23 TR TR2019/03672T patent/TR201903672T4/tr unknown
- 2015-12-23 MD MDA20170070A patent/MD4650B1/ro not_active IP Right Cessation
- 2015-12-23 ES ES18213309T patent/ES2900810T3/es active Active
- 2015-12-23 EP EP18213309.0A patent/EP3521282B1/en active Active
- 2015-12-23 PT PT182133090T patent/PT3521282T/pt unknown
- 2015-12-23 MA MA048448A patent/MA48448A/fr unknown
- 2015-12-23 EP EP21187414.4A patent/EP3960735B1/en active Active
- 2015-12-23 CU CUP2017000089A patent/CU20170089A7/es unknown
- 2015-12-23 PL PL15832711T patent/PL3237398T3/pl unknown
- 2015-12-23 CN CN202010295176.XA patent/CN111574464A/zh active Pending
- 2015-12-23 CR CR20170281A patent/CR20170281A/es unknown
-
2017
- 2017-06-21 IL IL25305917A patent/IL253059B/en active IP Right Grant
- 2017-06-22 SV SV2017005471A patent/SV2017005471A/es unknown
- 2017-06-22 DO DO2017000151A patent/DOP2017000151A/es unknown
- 2017-06-22 CO CONC2017/0006214A patent/CO2017006214A2/es unknown
- 2017-06-22 CL CL2017001675A patent/CL2017001675A1/es unknown
- 2017-06-22 EC ECIEPI201739611A patent/ECSP17039611A/es unknown
- 2017-06-23 MX MX2019009932A patent/MX2019009932A/es unknown
- 2017-06-23 PH PH12017501191A patent/PH12017501191B1/en unknown
- 2017-06-24 SA SA517381826A patent/SA517381826B1/ar unknown
- 2017-06-27 US US15/634,527 patent/US10206926B2/en active Active
-
2018
- 2018-07-04 JP JP2018127603A patent/JP2018168181A/ja active Pending
-
2019
- 2019-01-04 US US16/239,578 patent/US10548898B2/en active Active
- 2019-09-25 IL IL269635A patent/IL269635B/en active IP Right Grant
- 2019-12-18 US US16/718,311 patent/US11304948B2/en active Active
-
2021
- 2021-11-10 CY CY20211100979T patent/CY1124726T1/el unknown
-
2022
- 2022-03-09 US US17/690,351 patent/US20230043136A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| SV2016005171A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CL2019001495A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih. | |
| ECSP17069696A (es) | Compuestos novedosos | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| CL2017001539A1 (es) | Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos | |
| UY36464A (es) | Compuestos de quinazolina |